BIAF Valuation

bioAffinity Technologies Inc

Add to Watchlist

Advanced Chart

0.249

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

BIAF Relative Valuation

BIAF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIAF is overvalued; if below, it's undervalued.

Historical Valuation

bioAffinity Technologies Inc (BIAF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.05 is considered Undervalued compared with the five-year average of -2.14. The fair price of bioAffinity Technologies Inc (BIAF) is between 0.53 to 0.74 according to relative valuation methord. Compared to the current price of 0.25 USD , bioAffinity Technologies Inc is Undervalued By 52.9%.

Relative Value

Fair Zone

0.53-0.74

Current Price：0.25

52.9%

Undervalued

-0.86

Trailing

Forward

0.00

EV/EBITDA

bioAffinity Technologies Inc. (BIAF) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.68

EV/EBIT

bioAffinity Technologies Inc. (BIAF) has a current EV/EBIT of -0.68. The 5-year average EV/EBIT is -0.98. The thresholds are as follows: Strongly Undervalued below -3.19, Undervalued between -3.19 and -2.08, Fairly Valued between 0.13 and -2.08, Overvalued between 0.13 and 1.23, and Strongly Overvalued above 1.23. The current Forward EV/EBIT of -0.68 falls within the Historic Trend Line -Fairly Valued range.

1.05

bioAffinity Technologies Inc. (BIAF) has a current PS of 1.05. The 5-year average PS is 0.95. The thresholds are as follows: Strongly Undervalued below -1.05, Undervalued between -1.05 and -0.05, Fairly Valued between 1.95 and -0.05, Overvalued between 1.95 and 2.95, and Strongly Overvalued above 2.95. The current Forward PS of 1.05 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

bioAffinity Technologies Inc. (BIAF) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.24. The thresholds are as follows: Strongly Undervalued below -4.34, Undervalued between -4.34 and -2.79, Fairly Valued between 0.31 and -2.79, Overvalued between 0.31 and 1.86, and Strongly Overvalued above 1.86. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

bioAffinity Technologies Inc. (BIAF) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

bioAffinity Technologies Inc (BIAF) has a current Price-to-Book (P/B) ratio of -3.29. Compared to its 3-year average P/B ratio of 2.78 , the current P/B ratio is approximately -218.17% higher. Relative to its 5-year average P/B ratio of 2.78, the current P/B ratio is about -218.17% higher. bioAffinity Technologies Inc (BIAF) has a Forward Free Cash Flow (FCF) yield of approximately -102.89%. Compared to its 3-year average FCF yield of -43.28%, the current FCF yield is approximately 137.74% lower. Relative to its 5-year average FCF yield of -43.28% , the current FCF yield is about 137.74% lower.

-3.29

P/B

Median3y

2.78

Median5y

2.78

-102.89

FCF Yield

Median3y

-43.28

Median5y

-43.28

Competitors Valuation Multiple

The average P/S ratio for BIAF's competitors is 6.74, providing a benchmark for relative valuation. bioAffinity Technologies Inc Corp (BIAF) exhibits a P/S ratio of 1.05, which is -84.38% above the industry average. Given its robust revenue growth of -47.05%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BIAF.O

bioAffinity Technologies Inc

Helius Medical Technologies Inc

Cardio Diagnostics Holdings Inc

Star Equity Holdings Inc

Autonomix Medical Inc

Performance Decomposition

Market capitalization of BIAF decreased by 83.40% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -88.01 to -319.88.

The secondary factor is the Revenue Growth, contributed -47.05%to the performance.

Overall, the performance of BIAF in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-47.05%

2.40M → 1.27M

Revenue Growth

263.46%

-88.01 → -319.88

Margin Expansion

-299.81%

0.18 → -0.36

P/E Change

-83.40%